Evaluations of daily teriparatide using finite-element analysis over 12 months in rheumatoid arthritis patients.
J Bone Miner Metab
; 39(2): 270-277, 2021 Mar.
Article
em En
| MEDLINE
| ID: mdl-32886175
ABSTRACT
INTRODUCTION:
The objective of this study was to quantitatively evaluate the effects of daily teriparatide on rheumatoid arthritis patients using predicted bone strength (PBS) assessed by quantitative computed tomography-based finite-element analysis (QCT/FEA) and using bone mineral density (BMD) assessed by dual-energy X-ray absorptiometry (DXA), and to prospectively investigate clinical determinants associated with PBS and BMD increases. MATERIALS ANDMETHODS:
Participants comprised 39 patients (mean age, 69 years; disease activity score assessing 28 joints with CRP, 3.0; previous vertebral fractures, 82%) enrolled in this study. BMD by DXA and PBS by QCT/FEA of lumbar spine (LS) and proximal femur were measured at baseline, and after 6 and 12 months. In the groups showing increases in these values, variables that may have affected these increases were evaluated using univariate logistic regression analysis.RESULTS:
Daily teriparatide treatment significantly increased not only LS BMD, but also LS PBS in RA patients with osteoporosis after both 6 and 12 months of treatment. Increases in N-terminal type I procollagen propeptide (PINP) at 1 and 3 months were significantly associated with increased LS PBS at 12 months according to univariate logistic regression analysis. The threshold value for increased PINP at 1 month for increased PBS at 12 months was 75 µg/L.CONCLUSIONS:
Increased LS PBS at 12 months was predicted by increased PINP at 1 month from baseline.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Artrite Reumatoide
/
Teriparatida
/
Análise de Elementos Finitos
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article